Merck's Roger Perlmutter makes a rare move, joining the board of a machine learning startup out to change the R&D world. And he has some thoughts on that
Back in 2013, after a stint running R&D at Amgen followed by some independent time roaming the industry, Roger Perlmutter rejoined Merck and dedicated himself entirely to restoring the glean to the pharma giant’s tarnished rep. And one of the first things he did was shed his board memberships on the for-profit side of the industry.
He only took one biotech board post since then — at a promising startup called Exonics — which was bought out by Vertex.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 150,300+ biopharma pros reading Endpoints daily — and it's free.